Sounds like good news for Maraviroc. Research studies and real world off-label use should get Maraviroc approved for use in other indication besides HIV. Safety concerns would be upgraded too.

I hope Leronlimab results can get a move on!

Don't the papers Lalezari is preparing about the results from Leronlimab trials seem like the
Top Line reports that should have been written at the end of the trials? Who was supposed to write those reports before - Amarex or Cytodyn?